PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies
- 3 February 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 21 (3) , 355-361
Abstract
Introduction: There has been a significant paradigm shift in the manner in which lymphoid malignancies are treated and managed. Treatment has been moving away from conventional chemotherapy and towards targeted therapy. The success of new classes of agents such as monoclonal antibodies, proteasome inhibitors and immunomodulatory derivatives has sparked further searches for novel pathways to inhibit. The Bruton's tyrosine kinase (Btk) pathway is a downstream mediator of the B-cell receptor (BCR) pathway, which is crucial in B-cell production and maintenance, and a potential therapeutic target. Areas covered: This review will summarize the current knowledge of the Btk pathway and its role in lymphoid malignancies. It will also discuss the present data about PCI-32765 in both the preclinical and clinical setting. Expert opinion: PCI-32765 is an oral irreversible Btk inhibitor with high potency and both preclinical and clinical activity in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Phase I studies have demonstrated that it is well tolerated and has an excellent safety profile. Further studies are ongoing as a single agent and in combination with other targeted and conventional therapies. PCI-32765 is a very promising targeted therapy, and the data from these trials will ultimately decide its future role and success.Keywords
This publication has 45 references indexed in Scilit:
- Malignant pirates of the immune systemNature Immunology, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsArthritis Research & Therapy, 2011
- Novel Therapeutics for Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraBlood, 2008
- Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionshipChromosome Research, 2008